Development of the Crohn's disease digestive damage score, the Lemann score
B Pariente, J Cosnes, S Danese… - Inflammatory bowel …, 2011 - academic.oup.com
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available
instruments measure disease activity at a specific point in time. An instrument to measure …
instruments measure disease activity at a specific point in time. An instrument to measure …
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents
Reports of autoimmune diseases, including psoriasis-and dermatitis-like skin reactions with
anti-tumor necrosis factor-α (TNF-α), are increasing, likely a reflection of the growing use of …
anti-tumor necrosis factor-α (TNF-α), are increasing, likely a reflection of the growing use of …
Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence
T Engel, DE Yung, C Ma, B Pariente, P WIls… - Digestive and Liver …, 2019 - Elsevier
Background Ustekinumab [UST] is effective in Crohn's disease (CD) in the UNITI studies.
Several real-world experience (RWE) studies with UST have been published to date. Our …
Several real-world experience (RWE) studies with UST have been published to date. Our …
Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease
B Pariente, JY Mary, S Danese, Y Chowers, P De Cruz… - Gastroenterology, 2015 - Elsevier
Background & Aims There is a need for a scoring system that provides a comprehensive
assessment of structural bowel damage, including stricturing lesions, penetrating lesions …
assessment of structural bowel damage, including stricturing lesions, penetrating lesions …
Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission …
G D'Haens, S Vermeire, G Lambrecht, F Baert… - Gastroenterology, 2018 - Elsevier
Background & Aims A combination of infliximab and immunomodulators is the most
efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their …
efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their …
Deep remission at 1 year prevents progression of early Crohn's disease
Background & Aims We investigated the effects of inducing deep remission in patients with
early Crohn's disease (CD). Methods We collected follow-up data from 122 patients (mean …
early Crohn's disease (CD). Methods We collected follow-up data from 122 patients (mean …
Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease
A Amiot, JC Grimaud, L Peyrin-Biroulet, J Filippi… - Clinical …, 2016 - Elsevier
Background & Aims Phase 3 trials have shown the efficacy of vedolizumab, which binds to
integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We …
integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We …
Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti–tumor necrosis factor agents
P Wils, Y Bouhnik, P Michetti, B Flourie, H Brixi… - Clinical …, 2016 - Elsevier
Background & Aims Ustekinumab, a human monoclonal antibody against the p40 subunit of
interleukins-12 and-23, is effective in inducing and maintaining remission in patients with …
interleukins-12 and-23, is effective in inducing and maintaining remission in patients with …
Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease
A Buisson, F Gonzalez, F Poullenot… - Inflammatory bowel …, 2017 - academic.oup.com
Background Objective control of intestinal inflammation during inflammatory bowel disease
(IBD) is becoming the main driver for medical treatment. However, the monitoring tools …
(IBD) is becoming the main driver for medical treatment. However, the monitoring tools …
Dramatic increase in incidence of ulcerative colitis and Crohn's disease (1988–2011): a population-based study of French adolescents
S Ghione, H Sarter, M Fumery… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Few data are available to describe the changes in incidence of pediatric-
onset inflammatory bowel disease (IBD). The aim of this study was to describe changes in …
onset inflammatory bowel disease (IBD). The aim of this study was to describe changes in …